Different GLP-1 medications, and different doses of the same medication, produce measurably different results across heart and metabolic health markers, according to an analysis pooling 19 randomized controlled trials involving 13,117 adults with overweight or obesity.
The finding is being framed as a step toward personalized obesity treatment. That framing is reasonable, but it needs a boundary: the analysis does not produce a validated tool for choosing a medication for an individual patient, and it does not change current prescribing guidance.
